Will Human Drug Mechanisms Work for Animals? Pharmaceutical Companies Target the Pet Market
Daewoong and HK inno.N Develop New Atopic Dermatitis Drugs for Dogs
Yuyu Pharma Targets Cat Biopharmaceuticals in the U.S.
"Animal Field Data Can Also Serve as Human Pharmaceutical Evidence"
Domestic pharmaceutical companies are expanding their business into the pet pharmaceuticals market, viewing it as a new growth engine. As the culture of treating pets as family spreads, spending on veterinary services and medications is rising in tandem. The domestic animal pharmaceutical market, once dominated by manufacturers of livestock medicines, is now broadening to include treatments for chronic diseases in companion dogs and cats.
According to the pharmaceutical industry on July 2, companies such as Daewoong Pharmaceutical, HK inno.N, and Yuyu Pharma—traditionally focused on human medicines—are accelerating their entry into the pet pharmaceuticals sector. Market research firm Global Market Insights projects that the global pet pharmaceuticals market will grow from $26.8 billion (about 41.6 trillion won) last year to $51.1 billion (about 79.3 trillion won) by 2035. It is analyzed that as pets age, long-term care is increasingly needed for conditions such as skin diseases, joint diseases, diabetes, and heart disease, driving demand for specialized therapeutics.
Daewoong Pharmaceutical has applied to the Animal and Plant Quarantine Agency for marketing approval of Flodicitinib, a treatment for atopic dermatitis in dogs. Flodicitinib is a JAK (Janus kinase) inhibitor candidate, and Daewoong Pharmaceutical is also conducting clinical trials of a human medicine based on the same compound. HK inno.N has completed Phase 3 clinical trials for its oral new drug IN-115314, also a treatment for atopic dermatitis in dogs, and has applied for marketing approval. This candidate, too, is a JAK inhibitor, and development of a human atopic dermatitis treatment using the same mechanism is underway.
Yuyu Pharma has targeted the U.S. market from the outset. The company invested $4.5 million to establish a U.S. holding company, Yuyu Venture, and plans to operate two pet business subsidiaries: Yuyu Bio and Mervins Pet Care. This strategy reflects the large scale of pet pharmaceutical consumption and the well-developed prescription-based veterinary market in the United States. Yuyu Pharma is positioning pet biopharmaceuticals as a new growth engine and is focusing on identifying drug candidates for feline psoriasis treatment.
Pharmaceutical firms are prioritizing skin diseases due to their market potential. Atopic dermatitis is considered a particularly lucrative segment within the pet pharmaceuticals market. This is because it is a chronic disease requiring repeated treatment and pet owners show a high willingness to pay. According to the '2025 Korea Pet Report' by the KB Financial Group Management Research Institute, the average medical expenditure per pet-owning household last year was 1.46 million won, nearly double the figure from the 2023 survey. Among all treatment expense categories, spending on skin diseases was the highest, accounting for 46.0%.
Skin diseases are also relatively straightforward for pharmaceutical companies with experience in human medicine to address. Although humans and dogs are different species, certain diseases such as atopic dermatitis share biological pathways related to inflammation, immunity, and itching. JAK inhibitors work by blocking the signaling of inflammatory cytokines, thereby reducing itching and skin inflammation. These similarities explain why JAK inhibitors are being developed as candidate treatments for canine atopic dermatitis.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An industry insider explained, "Developing the same compound for both human and animal indications has become a widespread strategy in the animal pharmaceutical market. Clinical field data from animals can be used as efficacy data in the approval process for human medicines, as humans and companion animals often share similar environments and disease etiologies." Another industry expert added, "Attempts to expand mechanisms or platforms proven in human medicines to animal medicines are increasing, but verifying safety and efficacy for each species remains the key challenge."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.